Stock PYPD POLYPID LTD.
Add to a list
To use this feature you must be a member
Log inSign up

PolyPid Ltd. Share Price

Equities

PYPD

IL0011326795

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 21:30:00 26/04/2024 BST 		5-day change 1st Jan Change
4.752 USD -1.12% Intraday chart for PolyPid Ltd. +8.01% +25.07%
02-14 Transcript : PolyPid Ltd., Q4 2023 Earnings Call, Feb 14, 2024
02-14 PolyPid Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI

Financials

Sales 2024 * - Sales 2025 * - Capitalization 22.8M 1.83B
Net income 2024 * -25M -2B Net income 2025 * -24M -1.92B EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-1.32 x
P/E ratio 2025 *
-2.01 x
Employees 61
Yield 2024 *
-
Yield 2025 *
-
Free-Float 69.92%
More Fundamentals * Assessed data

Chart PolyPid Ltd.

Dynamic Chart

Latest news about PolyPid Ltd.

Transcript : PolyPid Ltd., Q4 2023 Earnings Call, Feb 14, 2024
PolyPid Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
PolyPid Ltd. Announces Enrollment of the 100th Patient in the Ongoing Shield II Phase 3 Trial CI
PolyPid Ltd. announced that it has received $35.01012 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc. CI
PolyPid Enters Into $16.2 Million Private Placement Deal MT
PolyPid Ltd. announced that it expects to receive $16.216011 million in funding from Dafna Capital Management, LLC, Rosalind Advisors, Inc. and other investors CI
Transcript : PolyPid Ltd., Q3 2023 Earnings Call, Nov 08, 2023
PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Polypid Announces the Addition of Dr. Nurit Tweezer-Zaks to Its Board of Directors CI
HC Wainwright Initiates PolyPid With Buy Rating, Price Target is $16 MT
Polypid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-Plex100 and Plex Technology Platform CI
Top Premarket Decliners MT
Top Premarket Decliners MT
PolyPid Facility for D-PLEX100 Has no Critical Findings From Israeli Health Ministry Audit MT
PolyPid to Implement 1-for-30 Reverse Stock Split MT
More news

Latest transcript on PolyPid Ltd.

Logo PolyPid Ltd.
PolyPid Ltd., Q4 2023 Earnings Call, Feb 14, 2024
More transcripts

Analyst Recommendations on PolyPid Ltd.

HC Wainwright Initiates PolyPid With Buy Rating, Price Target is $16 MT
Barclays Downgrades PolyPid to Equalweight From Overweight, Adjusts Price Target to $2.50 From $22 MT
Raymond James Downgrades PolyPid to Outperform From Strong Buy, Adjusts Price Target to $4 From $15 MT
BMO Capital Adjusts PolyPid's Price Target to $25 from $27, Keeps Outperform Rating MT
POLYPID : JMP Securities Starts PolyPid at Market Outperform With $14 Price Target MT
More recommendations

Press releases PolyPid Ltd.

PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024 AQ
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference AQ
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results AQ
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial AQ
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024 AQ
More press releases

Quotes and Performance

1 day-1.12%
1 week+8.01%
Current month+3.32%
1 month+1.12%
3 months-27.44%
6 months+25.73%
Current year+25.07%
More quotes

Highs and lows

1 week
4.40
Extreme 4.4
4.90
1 month
4.20
Extreme 4.2
4.95
Current year
4.10
Extreme 4.1
9.20
1 year
3.57
Extreme 3.5655
13.48
3 years
3.57
Extreme 3.5655
289.20
5 years
3.57
Extreme 3.5655
583.50
10 years
3.57
Extreme 3.5655
583.50
More quotes

Managers and Directors - PolyPid Ltd.

Managers TitleAgeSince
Dikla Akselbrad CEO
 Chief Executive Officer 50 30/06/14
Jonny Missulawin DFI
 Director of Finance/CFO 37 -
Olga Belotserkovsky CTO
 Chief Tech/Sci/R&D Officer - 29/02/16
Members of the board TitleAgeSince
Robert Stein BRD
 Director/Board Member 73 29/02/20
Itzhak Krinsky BRD
 Director/Board Member 71 30/11/18
Yechezkel Barenholz BRD
 Director/Board Member 82 31/03/08
More insiders

Quotes

Date Price Change Volume
26/04/24 4.752 -1.12% 2,321
25/04/24 4.806 +5.47% 1,523
24/04/24 4.557 +1.62% 885
23/04/24 4.484 +1.34% 905
22/04/24 4.425 +0.57% 3,559

Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm

More quotes

Company Profile

Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Sector
Pharmaceuticals
Calendar
07/05/2024 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
4.752 USD
Average target price
12.33 USD
Spread / Average Target
+159.51%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
POLYPID LTD. Stock PolyPid Ltd.
+25.07% 22.8M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PYPD Stock